Skip Ribbon Commands
Skip to main content
Sign In

24970 Beta-Crosslaps (Beta-CTx), Serum (CTX)

Beta-Crosslaps (Beta-CTx), Serum (CTX)
Test Code: BCTXSO
Synonyms/Keywords
B-CTx, Beta CrossLaps, Beta-CTx, C-Telopeptide, C-terminal collagen crosslinks, Carboxy terminal collagen crosslinks, CTx
Useful For
Monitoring antiresorptive therapies (eg, bisphosphonates and hormone replacement therapy) in postmenopausal women treated for osteoporosis and individuals diagnosed with osteopenia
 
An adjunct in the diagnosis of medical conditions associated with increased bone turnover
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Fasting. Draw specimen prior to 10 a.m.​ Serum​ ​Red Top tube (RTT) ​Serum Separator Tube (SST) 1 mL​ ​0.75 mL
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ Frozen (preferred) ​90 days
Refrigerated ​ ​72 hours
Rejection Criteria
Hemolysis
Gross reject
Interference

Reduced kidney function may lead to reduced urinary excretion of beta-C-terminal telopeptide (CTx) and a consequent increase in the apparent serum beta-CTx concentration.

As with all tests containing monoclonal mouse antibodies, erroneous findings may be obtained from specimens taken from patients treated with monoclonal mouse antibodies or have received them for diagnostic purposes.

In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies (HAMA) or heterophile antibodies), which may cause interference in some immunoassays. The presence of antibodies to streptavidin or ruthenium can also rarely occur and may interfere in this assay. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation. 

Serum biotin concentrations up to 1200 ng/mL do not interfere with this assay. Concentrations up to 1200 ng/mL may be present in specimens collected from patients taking extremely high doses of biotin up to 300 mg per day. In a study among 54 healthy volunteers, supplementation with 20 mg/day biotin resulted in a maximum serum biotin concentration of 355 ng/mL 1-hour post-dose.

Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available Methodology/Instrumentation
Mayo Clinic Laboratories​​ Monday through Friday ​
1 to 3 days
Electrochemiluminescence Immunoassay (ECLIA)
Reference Lab
Reference Range Information

 

Males

<5 years: 242-1292 pg/mL

5-9 years: 351-1532 pg/mL

10-15 years: 447-2457 pg/mL

16-17 years: 478-1666 pg/mL

18-29 years: 238-1019

30-39 years: 225-936

40-49 years: 182-801

50-59 years: 161-737

60-69 years: 132-752

>70 years: 118-776

 

Females

<5 years: 347-1508 pg/mL

5-9 years: 383-1556 pg/mL

10-15 years: 311-1776 pg/mL

16-17 years: 146-1266 pg/mL

18-29 years: 148-967

30-39 years: 150-635

40-49 years: 131-670

50-59 years: 183-1060

60-69 years: 171-970

>70 years: 152-858

Premenopausal: 136-689 pg/mL

Postmenopausal: 177-1015 pg/mL

Interpretation
Elevated levels of beta-CTx indicate increased bone resorption. Increased levels are associated with osteoporosis, osteopenia, Paget's disease, hyperthyroidism, and hyperparathyroidism.
 
In patients taking antiresorptive agents (bisphosphonates or hormone replacement therapy), a decrease of 25% or more from baseline beta-CTx levels (ie, prior to the start of therapy) 3 to 6 months after initiation of therapy indicates an adequate therapeutic response.
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​82523
Synonyms/Keywords
B-CTx, Beta CrossLaps, Beta-CTx, C-Telopeptide, C-terminal collagen crosslinks, Carboxy terminal collagen crosslinks, CTx
Ordering Applications
Ordering Application Description
​Cerner ​Beta-CrossLaps (Beta-CTx), Serum (CTX)
​COM ​Beta-CrossLaps (B-CTx), Serum (CTX)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Fasting. Draw specimen prior to 10 a.m.​ Serum​ ​Red Top tube (RTT) ​Serum Separator Tube (SST) 1 mL​ ​0.75 mL
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ Frozen (preferred) ​90 days
Refrigerated ​ ​72 hours
Rejection Criteria
Hemolysis
Gross reject
Interference

Reduced kidney function may lead to reduced urinary excretion of beta-C-terminal telopeptide (CTx) and a consequent increase in the apparent serum beta-CTx concentration.

As with all tests containing monoclonal mouse antibodies, erroneous findings may be obtained from specimens taken from patients treated with monoclonal mouse antibodies or have received them for diagnostic purposes.

In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies (HAMA) or heterophile antibodies), which may cause interference in some immunoassays. The presence of antibodies to streptavidin or ruthenium can also rarely occur and may interfere in this assay. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation. 

Serum biotin concentrations up to 1200 ng/mL do not interfere with this assay. Concentrations up to 1200 ng/mL may be present in specimens collected from patients taking extremely high doses of biotin up to 300 mg per day. In a study among 54 healthy volunteers, supplementation with 20 mg/day biotin resulted in a maximum serum biotin concentration of 355 ng/mL 1-hour post-dose.

Useful For
Monitoring antiresorptive therapies (eg, bisphosphonates and hormone replacement therapy) in postmenopausal women treated for osteoporosis and individuals diagnosed with osteopenia
 
An adjunct in the diagnosis of medical conditions associated with increased bone turnover
Reference Range Information

 

Males

<5 years: 242-1292 pg/mL

5-9 years: 351-1532 pg/mL

10-15 years: 447-2457 pg/mL

16-17 years: 478-1666 pg/mL

18-29 years: 238-1019

30-39 years: 225-936

40-49 years: 182-801

50-59 years: 161-737

60-69 years: 132-752

>70 years: 118-776

 

Females

<5 years: 347-1508 pg/mL

5-9 years: 383-1556 pg/mL

10-15 years: 311-1776 pg/mL

16-17 years: 146-1266 pg/mL

18-29 years: 148-967

30-39 years: 150-635

40-49 years: 131-670

50-59 years: 183-1060

60-69 years: 171-970

>70 years: 152-858

Premenopausal: 136-689 pg/mL

Postmenopausal: 177-1015 pg/mL

Interpretation
Elevated levels of beta-CTx indicate increased bone resorption. Increased levels are associated with osteoporosis, osteopenia, Paget's disease, hyperthyroidism, and hyperparathyroidism.
 
In patients taking antiresorptive agents (bisphosphonates or hormone replacement therapy), a decrease of 25% or more from baseline beta-CTx levels (ie, prior to the start of therapy) 3 to 6 months after initiation of therapy indicates an adequate therapeutic response.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available Methodology/Instrumentation
Mayo Clinic Laboratories​​ Monday through Friday ​
1 to 3 days
Electrochemiluminescence Immunoassay (ECLIA)
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​82523
For most current information refer to the Marshfield Laboratory online reference manual.